1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Insulin Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Insulin Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Increase in diabetes prevalence
- 5.1.2 Growth in demand for insulin therapies
5.2 Market Opportunities
- 5.2.1 Expansion in diabetes management market
- 5.2.2 Growth in insulin pen and pump usage
5.3 Future Trends
- 5.3.1 Increasing adoption of insulin pumps and pens
- 5.3.2 Development of insulin biosimilars and new delivery technologies
5.4 Impact of Drivers and Restraints
6. Europe Insulin Market Regional Analysis
6.1 Europe Insulin Market Overview
6.2 Europe Insulin Market Revenue 2020-2028 (US$ Million)
6.3 Europe Insulin Market Forecast Analysis
7. Europe Insulin Market Analysis – by Type
7.1 Long Acting Insulin
- 7.1.1 Overview
- 7.1.2 Long Acting Insulin: Europe Insulin Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Rapid Acting Insulins
- 7.2.1 Overview
- 7.2.2 Rapid Acting Insulins: Europe Insulin Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Short acting Insulins and Traditional Human Insulins
- 7.3.1 Overview
- 7.3.2 Short acting Insulins and Traditional Human Insulins: Europe Insulin Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Concentrated Insulins and Combination Insulins
- 7.4.1 Overview
- 7.4.2 Concentrated Insulins and Combination Insulins: Europe Insulin Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Biosimilar Insulins
- 7.5.1 Overview
- 7.5.2 Biosimilar Insulins: Europe Insulin Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Glucagon-like peptide-1
- 7.6.1 Overview
- 7.6.2 Glucagon-like peptide-1: Europe Insulin Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Pens and Needles
- 7.7.1 Overview
- 7.7.2 Pens and Needles: Europe Insulin Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Insulin Market – Europe Analysis
8.1 Europe
- 8.1.1 Europe Insulin Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 8.1.1.1 Europe Insulin Market – Revenue and
Forecast Analysis – by Country
- 8.1.1.1 UK:
Europe Insulin Market – Revenue and Forecast to 2028 (US$ Million)
- 8.1.1.1.1 UK: Europe Insulin Market Breakdown, by Type
- 8.1.1.2 Germany:
Europe Insulin Market – Revenue and Forecast to 2028 (US$ Million)
- 8.1.1.2.1 Germany: Europe Insulin Market Breakdown, by Type
- 8.1.1.3 France:
Europe Insulin Market – Revenue and Forecast to 2028 (US$ Million)
- 8.1.1.3.1 France: Europe Insulin Market Breakdown, by Type
- 8.1.1.4 Russia:
Europe Insulin Market – Revenue and Forecast to 2028 (US$ Million)
- 8.1.1.4.1 Russia: Europe Insulin Market Breakdown, by Type
- 8.1.1.5 Italy:
Europe Insulin Market – Revenue and Forecast to 2028 (US$ Million)
- 8.1.1.5.1 Italy: Europe Insulin Market Breakdown, by Type
- 8.1.1.6 Rest of Europe:
Europe Insulin Market – Revenue and Forecast to 2028 (US$ Million)
- 8.1.1.6.1 Rest of Europe: Europe Insulin Market Breakdown, by Type
9. Competitive Landscape
9.1 Heat Map Analysis
9.2 Company Positioning and Concentration
10. Europe Insulin Market Industry Landscape
10.1 Overview
10.2 Mergers and Acquisitions
10.3 Agreements, Collaborations, and Joint Ventures
10.4 New Product Launches
10.5 Expansions and Other Strategic Developments
11. Company Profiles
11.1 Adocia
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Biocon
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Eli Lilly and Company
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 GlaxoSmithKline plc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Merck & Co., Inc.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Novo Nordisk A/S
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Pfizer Inc.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Sanofi
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Tonghua Dongbao Pharmaceutical Co., Ltd.
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Wockhardt
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments
12. Appendix
12.1 About Business Market Insights
Get Free Sample For Europe Insulin Market
